AstraZeneca PLC (AZN)vsHealthStream Inc (HSTM)
AZN
AstraZeneca PLC
$158.75
-0.16%
HEALTHCARE · Cap: $263.09B
HSTM
HealthStream Inc
$28.36
0.00%
HEALTHCARE · Cap: $839.77M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 19010% more annual revenue ($61.37B vs $321.12M). AZN leads profitability with a 17.0% profit margin vs 6.6%. AZN appears more attractively valued with a PEG of 1.47. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
HSTM
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.3%
Fair Value
$196.68
Current Price
$158.75
$37.93 discount
Intrinsic value data unavailable for HSTM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 28.4% YoY
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 5.7% — below average capital efficiency
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : HSTM
The strongest argument for HSTM centers on Debt/Equity, Price/Book, EPS Growth. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : HSTM
The primary concerns for HSTM are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while HSTM is a value play — different risk/reward profiles.
HSTM carries more volatility with a beta of 0.44 — expect wider price swings.
HSTM is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 51/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
HealthStream Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
HealthStream, Inc. provides provider and staff solutions for healthcare organizations in the United States. The company is headquartered in Nashville, Tennessee.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?